 |
|
Home | Kite Pharma Rating Lowered to Sell at Zacks (KITE) |
 |
Kite Pharma Rating Lowered to Sell at Zacks (KITE)
|
 |
- June 02, 2015
-
Kite Pharma (NASDAQ:KITE) was downgraded by Zacks from a “hold” rating to a “sell” rating in a research note issued to investors on Monday. Zacks’ analyst wrote, “Kite is focused on the development of immuno-oncology treatments. The company is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer. Kite […]This article (Kite Pharma Rating Lowered to Sell at Zacks (KITE)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2015/06/01/kite-pharma-rating-lowered-to-sell-at-zacks-kite/
|
 |
|
 |
|
 |
